

# Fausto Andreola

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9539277/publications.pdf>

Version: 2024-02-01

54  
papers

1,789  
citations

257450  
24  
h-index

276875  
41  
g-index

54  
all docs

54  
docs citations

54  
times ranked

2578  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of TLR7 and TLR9 Reduces Human Cholangiocarcinoma Cell Proliferation and Tumor Development. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1806-1821.	2.3	6
2	The role of RIPK1 mediated cell death in acute on chronic liver failure. <i>Cell Death and Disease</i> , 2022, 13, 5.	6.3	22
3	Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation. <i>Scientific Reports</i> , 2022, 12, 3418.	3.3	19
4	Editorial: The Role of Microbiota in the Onset and Development of Intestine and Liver Diseases and Cancer: Molecular and Cell Mechanisms. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 852188.	3.7	1
5	Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF. <i>Journal of Hepatology</i> , 2022, 77, 1325-1338.	3.7	31
6	Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 71, 874-892.	7.3	62
7	Exogenous Liposomal Ceramide-C6 Ameliorates Lipidomic Profile, Energy Homeostasis, and Anti-Oxidant Systems in NASH. <i>Cells</i> , 2020, 9, 1237.	4.1	13
8	Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure. <i>Journal of Hepatology</i> , 2020, 73, 102-112.	3.7	94
9	Recombinant Alkaline Phosphatase Prevents Acute on Chronic Liver Failure. <i>Scientific Reports</i> , 2020, 10, 389.	3.3	32
10	Ammonia: A novel target for the treatment of non-alcoholic steatohepatitis. <i>Medical Hypotheses</i> , 2018, 113, 91-97.	1.5	34
11	Cell death markers in patients with cirrhosis and acute decompensation. <i>Hepatology</i> , 2018, 67, 989-1002.	7.3	76
12	Urea cycle dysregulation in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2018, 69, 905-915.	3.7	123
13	Reactive gamma-ketoaldehydes as novel activators of hepatic stellate cells in vitro. <i>Free Radical Biology and Medicine</i> , 2017, 102, 162-173.	2.9	11
14	Human Serum Albumin administration prevents cell death-derived extracellular nucleosomes and core-histones-driven inflammasome activation and portal hypertension in Acute on Chronic Liver Failure. <i>Journal of Hepatology</i> , 2017, 66, S579.	3.7	0
15	Early Increase in Ammonia Is A Feature of Non-Alcoholic Fatty Liver Disease and the Ammonia Lowering Drug, Ornithine Phenylacetate (OCR002) Prevents Progression of Fibrosis in A Rodent Model. <i>Journal of Clinical and Experimental Hepatology</i> , 2017, 7, S73-S74.	0.9	2
16	Early increase in ammonia is a feature of non-alcoholic fatty liver disease and the ammonia lowering drug, ornithine phenylacetate (OCR-002) prevents progression of fibrosis in a rodent model. <i>Journal of Hepatology</i> , 2017, 66, S170.	3.7	4
17	New technologies “ new insights into the pathogenesis of hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2016, 31, 1259-1267.	2.9	8
18	Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension. <i>Journal of Hepatology</i> , 2016, 64, 823-833.	3.7	80

#	ARTICLE	IF	CITATIONS
19	PTU-090...Circulating Level of End Product of Apoptosis Caspase-Cleaved Keratin 18 Reflects Clinical Severity in Acute on Chronic Liver Disease and Is A Potential Biomarker for Diagnosis and Therapeutic Monitoring. Gut, 2016, 65, A98.3-A99.	12.1	0
20	P0437 : Reactive gamma-ketoaldehydes as novel activators of hepatic stellate cells in vitro. Journal of Hepatology, 2015, 62, S477.	3.7	1
21	P0291 : The oncostatic action of sorafenib on liver cancer cells is changed to an oncolytic effect following pre-treatment with chloroquine: Demonstration of synergy between chloroquine and sorafenib as a potential novel approach to treatment of HCC. Journal of Hepatology, 2015, 62, S417.	3.7	0
22	Circulating microRNAs Reveal Time Course of Organ Injury in a Porcine Model of Acetaminophen-Induced Acute Liver Failure. PLoS ONE, 2015, 10, e0128076.	2.5	29
23	P0423 : Role of apoptic DNA and extracellular core histones in inflammasome activation in primary human hepatic stellate cells. Journal of Hepatology, 2015, 62, S472.	3.7	1
24	P0443 : Hyperammonemia activates human hepatic stellate cells and is a target for treatment of portal hypertension. Journal of Hepatology, 2015, 62, S478-S479.	3.7	0
25	Mechanism of cell death in acute-on-chronic liver failure: a clinico-pathologic biomarker study. Liver International, 2015, 35, 2564-2574.	3.9	34
26	Extracorporeal liver assist device to exchange albumin and remove endotoxin in acute liver failure: Results of a pivotal pre-clinical study. Journal of Hepatology, 2015, 63, 634-642.	3.7	56
27	Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure. Journal of Hepatology, 2015, 62, 799-806.	3.7	73
28	Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver International, 2015, 35, 1063-1076.	3.9	53
29	P105 ACTIVATION OF SENESCENT GENES IN CHRONIC AND ACUTE-ON-CHRONIC LIVER FAILURE RAT BRAINS. Journal of Hepatology, 2014, 60, S101.	3.7	1
30	Identification of potential serum peptide biomarkers of biliary tract cancer using MALDI MS profiling. BMC Clinical Pathology, 2014, 14, 7.	1.8	20
31	P91 EFFECT OF TOLL-LIKE RECEPTOR 7 AND 9 TARGETED THERAPY TO PREVENT THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2014, 60, S96-S97.	3.7	0
32	Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer. Cancer, 2013, 119, 575-585.	4.1	33
33	1064 TARGETING TLR7 AND 9: A NOVEL STRATEGY FOR TREATMENT OF CHOLANGIOCARCINOMA. Journal of Hepatology, 2013, 58, S436-S437.	3.7	0
34	Whole genome RNA expression profiling of endoscopic biliary brushings provides data suitable for biomarker discovery in cholangiocarcinoma. Journal of Hepatology, 2012, 56, 877-885.	3.7	43
35	Circulating CYFRA 21-1 is a Specific Diagnostic and Prognostic Biomarker in Biliary Tract Cancer. Journal of Clinical and Experimental Hepatology, 2011, 1, 6-12.	0.9	48
36	A combination of serum leucine-rich $\alpha$ 2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. British Journal of Cancer, 2011, 105, 1370-1378.	6.4	63

#	ARTICLE	IF	CITATIONS
37	PWE-055â€...Characterisation of serum proteins in biliary tract cancer, primary sclerosing cholangitis and immunoglobulin G4-associated cholangitis using 2-dimensional difference gel electrophoresis and tandem mass spectrometry. <i>Gut</i> , 2010, 59, A106.2-A107.	12.1	0
38	PTU-082â€...Serum CEACAM1 in the preclinical diagnosis of pancreatic adenocarcinoma. <i>Gut</i> , 2010, 59, A82.1-A82.	12.1	0
39	Role of aquaporin-4 in the development of brain oedema in liver failure. <i>Journal of Hepatology</i> , 2010, 53, 91-97.	3.7	56
40	Effect of verteporfin-PDT on the Notch signaling pathway in cholangiocarcinoma (CCA) cell lines. <i>Proceedings of SPIE</i> , 2009, , .	0.8	0
41	Effect of verteporfin-PDT on epithelial growth factor receptor (EGFR) signaling pathway in cholangiocarcinoma cell lines. <i>Proceedings of SPIE</i> , 2009, , .	0.8	0
42	MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer. <i>British Journal of Cancer</i> , 2008, 98, 1675-1681.	6.4	56
43	The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARÂ pathway. <i>Carcinogenesis</i> , 2004, 25, 1805-1812.	2.8	26
44	Mouse Liver CYP2C39 Is a Novel Retinoic Acid 4-Hydroxylase. <i>Journal of Biological Chemistry</i> , 2004, 279, 3434-3438.	3.4	58
45	Reversal of liver fibrosis in aryl hydrocarbon receptornull mice by dietary vitamin A depletion. <i>Hepatology</i> , 2004, 39, 157-166.	7.3	38
46	Human melanomas of fibroblast and epithelial morphology differ widely in their ability to synthesize retinyl esters. <i>Carcinogenesis</i> , 2002, 23, 1821-1830.	2.8	10
47	Differences in uptake and metabolism of retinoic acid between estrogen receptor-positive and -negative human breast cancer cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 128-134.	2.3	17
48	Retinoids in chemoprevention and differentiation therapy. <i>Carcinogenesis</i> , 2000, 21, 1271-1279.	2.8	234
49	Expression of a Smaller Lecithin:Retinol Acyl Transferase Transcript and Reduced Retinol Esterification in MCF-7 Cells. <i>Biochemical and Biophysical Research Communications</i> , 2000, 279, 920-924.	2.1	16
50	Retinoids in chemoprevention and differentiation therapy. <i>Carcinogenesis</i> , 2000, 21, 1271-1279.	2.8	57
51	Retinoic acid and 4-hydroxyphenylretinamide induce growth inhibition and tissue transglutaminase through different signal transduction pathways in mouse fibroblasts (NIH 3T3 cells). <i>Carcinogenesis</i> , 1999, 20, 1133-1135.	2.8	13
52	The Cloning and Characterization of a Novel Cytochrome P450 Family, CYP26, with Specificity Toward Retinoic Acid. <i>Nutrition Reviews</i> , 1998, 56, 84-85.	5.8	22
53	The role of vitamin A in differentiation and skin carcinogenesis. <i>Journal of Nutritional Biochemistry</i> , 1997, 8, 426-437.	4.2	24
54	Aryl hydrocarbon receptor knockout mice (AHR-/-) exhibit liver retinoid accumulation and reduced retinoic acid metabolism. <i>Cancer Research</i> , 1997, 57, 2835-8.	0.9	89